Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

French drug major Sanofi and the US unit of Israel’s Teva Pharmaceutical Industries have presented new, detailed results from the RELIEVE UCCD Phase IIb study of duvakitug, a human IgG1-λ2 monoclonal ...

Conference call to discuss new data presented for duvakitug (Anti-TL1A) positive Phase 2b results at the 20th Annual Congress of the European ...

The analyst will closely follow what Teva shares on this at the upcoming ECCO meeting ... Teva/Sanofi’s all-comers Phase III program for duvakitug is commercially reasonable, the goal is ...

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified ... Crohn’s and Colitis Organisation (ECCO) in Berlin, Germany.

Find earnings, economic, stock splits and IPO calendars to track upcoming financial events from Yahoo Finance.

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified ... Crohn’s and Colitis Organisation (ECCO) in Berlin, Germany.